These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 12490967

  • 1. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M.
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [Abstract] [Full Text] [Related]

  • 2. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [Abstract] [Full Text] [Related]

  • 3. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H.
    Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
    [Abstract] [Full Text] [Related]

  • 4. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC, de Valois JC, van den Ende B, Wouter ten Cate J, Kastelein JJ.
    Atherosclerosis; 1996 Jul; 124 Suppl():S75-81. PubMed ID: 8831919
    [Abstract] [Full Text] [Related]

  • 5. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
    Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF.
    Int Angiol; 1998 Dec; 17(4):225-33. PubMed ID: 10204653
    [Abstract] [Full Text] [Related]

  • 6. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
    Hernández-Mijares A, Lluch I, Vizcarra E, Martínez-Triguero ML, Ascaso JF, Carmena R.
    Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):1-6. PubMed ID: 10812581
    [Abstract] [Full Text] [Related]

  • 7. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
    Petit D, Bonnefis MT, Rey C, Infante R.
    Atherosclerosis; 1988 Dec; 74(3):215-25. PubMed ID: 3240333
    [Abstract] [Full Text] [Related]

  • 8. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
    Espinosa RA, Rodríguez-Roa E, Nagy E, Mijares ME, Rodríguez-Larralde A, Gil A, Lundberg U, Carvajal Z, Castillo L, Arocha-Piñango CL.
    Invest Clin; 2006 Mar; 47(1):35-48. PubMed ID: 16562643
    [Abstract] [Full Text] [Related]

  • 9. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
    Bruckert E, Dejager S, Chapman MJ.
    Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
    [Abstract] [Full Text] [Related]

  • 10. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
    Kovács I, Tarján J, Császár A.
    Orv Hetil; 2001 Apr 15; 142(15):775-9. PubMed ID: 11367862
    [Abstract] [Full Text] [Related]

  • 11. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
    Am J Ther; 2007 Apr 15; 14(2):213-20. PubMed ID: 17414592
    [Abstract] [Full Text] [Related]

  • 12. Effect of ciprofibrate on lipoprotien metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype.
    Raslová K, Nagyová A, Dobiásová M, Ptácková K, Dusinská M.
    Acta Diabetol; 2000 Apr 15; 37(3):131-4. PubMed ID: 11277313
    [Abstract] [Full Text] [Related]

  • 13. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG, Orö L.
    Atherosclerosis; 1982 Apr 15; 42(2-3):229-43. PubMed ID: 6951582
    [Abstract] [Full Text] [Related]

  • 14. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
    Rizos E, Kostoula A, Elisaf M, Mikhailidis DP.
    Angiology; 2002 Apr 15; 53(3):273-7. PubMed ID: 12025914
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
    Cattin L, Da Col PG, Feruglio FS, Finazzo L, Rimondi S, Descovich G, Manzato E, Zambon S, Crepaldi G, Siepi D.
    Clin Ther; 1990 Apr 15; 12(6):482-8. PubMed ID: 2289217
    [Abstract] [Full Text] [Related]

  • 16. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
    Chapman MJ, Bruckert E.
    Atherosclerosis; 1996 Jul 15; 124 Suppl():S21-8. PubMed ID: 8831912
    [Abstract] [Full Text] [Related]

  • 17. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL, Cater NB, Hadizadeh DR, Meguro S, Grundy SM.
    Clin Pharmacol Ther; 2003 Sep 15; 74(3):236-44. PubMed ID: 12966367
    [Abstract] [Full Text] [Related]

  • 18. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M, Mongiellová V, Huttová D, Cibulová L, Krivosíková Z, Spustová V, Dzúrik R.
    J Cardiovasc Pharmacol; 2001 Nov 15; 38(5):651-6. PubMed ID: 11602811
    [Abstract] [Full Text] [Related]

  • 19. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M, Le Goff W, Frisdal E, Schneider S, Milosavljevic D, Bruckert E, Chapman MJ.
    J Clin Endocrinol Metab; 2003 Aug 15; 88(8):3738-46. PubMed ID: 12915663
    [Abstract] [Full Text] [Related]

  • 20. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.
    Paragh G, Seres I, Harangi M, Erdei A, Audikovszky M, Debreczeni L, Kovácsay A, Illyés L, Pados G.
    Br J Clin Pharmacol; 2006 Jun 15; 61(6):694-701. PubMed ID: 16722831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.